|
Mara G. Aspinall, President, Genetics, Genzyme Corporation
Dr Peter T. C. Ho, Senior Vice President of Oncology Center of Excellence for Drug Discovery, GlaxoSmithKline
Barry M. Straube, MD, CMS Chief Medical Officer & Director, Office of Clinical Standards & Quality, Centers for Medicare & Medicaid Services
Dr Lawrence Shulman, Chief Medical Officer, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute & Director, Network Development, Dana-Farber/Brigham & Women's Cancer Care
Dr Brent M. Vose, Vice President & Head of Oncology & Infection, AstraZeneca
Professor Sir Michael Rawlins, Chairman, National Institute for Clinical Excellence
Kapil Dhingra, MD, Head of the Oncology Global Drug Development Group, Hoffmann-La Roche, Inc
Lee F. Allen, MD, PhD, Cambridge Site Head, Vice President, Medical Research - Oncology Therapeutic Area, Wyeth Research
Christopher Seaton, Senior Vice President, Global Business Development & Licensing, Bayer Corporation
Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association
Steven D. Harr, Managing Director & Analyst, Morgan Stanley
Dr Roy Baynes, Vice President, Clinical Development, Therapeutic Area Head, Oncology Supportive Care, Amgen, Inc
Donald P. Rosen, MD, Founder & Chief Strategy Officer, RadPharm
Dr Stephen Kelsey, Vice President & Head of Exploratory Clinical Development, BioOncology, Genentech, Inc
Dr Doris Slate, Vice President, Scientific Licensing, Johnson & Johnson
Dr Nicholas C. Dracopoli, Vice President, Clinical Discovery Technologies, Bristol-Myers Squibb Pharmaceutical Research Institute
Geert Kolvenbag, MD, PhD, Executive Director of Development, Emerging Oncology Brands, AstraZeneca
Dr David Chang, Vice President, Global Clinical Development, Oncology Therapeutics, Amgen
Joe Monforte, PhD, Vice President, Chief Scientific Officer, Althea Technologies
Dr Maryellen de Mars, Director of Clinical Biomarkers, The Critical Path Institute (C-Path)
|
Dr David Urdal, Chief Scientific Officer, Dendreon Corporation
Thomas R. Barr, MBA, COO, Oncology Metrics, LLC
Dr Ulrik B. Nielsen, Vice President of Research, Merrimack Pharmaceuticals
Jeffrey D. Bloss, MD, Vice President, Clinical Development, Onyx Pharmaceuticals, Inc
Dr Francis Kalush, Molecular Diagnostics, Office of In Vitro Diagnostics (OIVD/CDRH), US Food & Drug Administration
Howard J. Fingert, MD, FACP, Senior Director & Clinical Lead, Signal Transduction Development Program, Pfizer Oncology
Professor James Carmichael, CMO, KuDOS Pharmaceuticals
Anne E. Hagey, MD, Global Project Head, Oncology Cytotoxics, Abbott Laboratories
Thomas G. Roberts, MD, MSocSci, Senior Health Care Analyst & Portfolio Manager, Noonday Asset Management, LP (sub-adviser to Farallon Capital Management, LLC)
Dr Jay Feingold, Assistant Vice President & Multi-Therapeutic Area Head, Global Medical Affairs, Wyeth Research
Dr Neil W. Gibson, Chief Scientific Officer, OSI Pharmaceuticals, Inc
Dr Robert L. Ilaria Jr, Medical Advisor for Oncology, Eli Lilly and Company
Dr Mark Sliwkowski, Staff Scientist & Director of Translational Oncology, Genentech, Inc
Dr Cheryl Marks, Associate Director, Division of Cancer Biology, & Director, Mouse Models of Human Cancers Consortium (MMHCC), National Cancer Institute
Thomas W. Griffin, MD, Executive Director, Therapeutic Area Head, Oncology Therapeutics, North American Medical Affairs, Amgen, Inc
Dr Bernhard Sixt, CEO & Founder, Agendia
Dr John Waterton, Chief Scientist, Translational Sciences, AstraZeneca
Dr Jens Oliver Funk, Head, Oncology Therapeutic Area, Merck Serono
Carlo Montagner, President, Abraxis Oncology
Dr C. Anthony Altar, Director, The Biomarkers Consortium
Dr Mark Chang, Director, Biostatistics, Millennium Pharmaceuticals, Inc
|
